Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of Travere Therapeutics Inc (NASDAQ: TVTX) closed at $20.79 in the last session, down -1.05% from day before closing price of $21.01. In other words, the price has decreased by -$1.05 from its previous closing price. On the day, 1.67 million shares were traded. TVTX stock price reached its highest trading level at $21.28 during the session, while it also had its lowest trading level at $20.2896.
Ratios:
We take a closer look at TVTX’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.04 and its Current Ratio is at 2.08. In the meantime, Its Debt-to-Equity ratio is 6.80 whereas as Long-Term Debt/Eq ratio is at 5.54.
On October 21, 2024, Wells Fargo Upgraded its rating to Overweight which previously was Equal Weight and also upped its target price recommendation from $9 to $27.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 12 ’25 when ROTE WILLIAM E. sold 5,200 shares for $23.53 per share. The transaction valued at 122,356 led to the insider holds 98,519 shares of the business.
REED ELIZABETH E sold 8,000 shares of TVTX for $188,240 on Feb 12 ’25. The SVP, GC & CORPORATE SECRETARY now owns 89,482 shares after completing the transaction at $23.53 per share. On Feb 11 ’25, another insider, Calvin Sandra, who serves as the SVP, CHIEF ACCOUNTING OFFICER of the company, sold 54,244 shares for $25.00 each. As a result, the insider received 1,356,100 and left with 54,410 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TVTX now has a Market Capitalization of 1864424320 and an Enterprise Value of 1875783936. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.91 while its Price-to-Book (P/B) ratio in mrq is 30.78. Its current Enterprise Value per Revenue stands at 8.045 whereas that against EBITDA is -8.822.
Stock Price History:
The Beta on a monthly basis for TVTX is 0.78, which has changed by 1.7392437 over the last 52 weeks, in comparison to a change of 0.10063088 over the same period for the S&P500. Over the past 52 weeks, TVTX has reached a high of $25.29, while it has fallen to a 52-week low of $5.12. The 50-Day Moving Average of the stock is 1.07%, while the 200-Day Moving Average is calculated to be 35.40%.
Shares Statistics:
According to the various share statistics, TVTX traded on average about 1.59M shares per day over the past 3-months and 1613610 shares per day over the past 10 days. A total of 87.45M shares are outstanding, with a floating share count of 87.41M. Insiders hold about 1.50% of the company’s shares, while institutions hold 109.22% stake in the company. Shares short for TVTX as of 1741910400 were 11194840 with a Short Ratio of 7.05, compared to 1739491200 on 11301636. Therefore, it implies a Short% of Shares Outstanding of 11194840 and a Short% of Float of 13.949998999999998.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
The market rating for Travere Therapeutics Inc (TVTX) is a result of the insights provided by 7.0 analysts actively involved in the assessment.The consensus estimate for the next quarter is -$0.2, with high estimates of -$0.08 and low estimates of -$0.35.
Analysts are recommending an EPS of between -$0.11 and -$0.63 for the fiscal current year, implying an average EPS of -$0.33. EPS for the following year is $1.61, with 8.0 analysts recommending between $3.52 and -$0.05.
Revenue Estimates
According to 12 analysts, the current quarter’s revenue is expected to be $77.53M. It ranges from a high estimate of $94.5M to a low estimate of $72.1M. As of the current estimate, Travere Therapeutics Inc’s year-ago sales were $41.37MFor the next quarter, 12 analysts are estimating revenue of $89.56M. There is a high estimate of $109M for the next quarter, whereas the lowest estimate is $77.76M.
A total of 15 analysts have provided revenue estimates for TVTX’s current fiscal year. The highest revenue estimate was $445.41M, while the lowest revenue estimate was $331.16M, resulting in an average revenue estimate of $391.74M. In the same quarter a year ago, actual revenue was $233.18MBased on 15 analysts’ estimates, the company’s revenue will be $602.36M in the next fiscal year. The high estimate is $870M and the low estimate is $403.19M.
